Magle Chemoswed Holding AB announces change of Certified Adviser to Redeye

MFN Publicerad: 16 Dec 13:33

Magle Chemoswed Holding AB (publ) hereby announces that the company has entered into an agreement with Redeye AB (“Redeye”) regarding the service as a Certified Adviser. Redeye will be appointed Certified Adviser (CA) on January 12, 2026. Up until then, Vator Securities will continue to act as Certified.

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmacept.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at [email protected] or +46 (0)8-580 065 99.

Pressmeddelande

Magle Chemoswed Holding AB announces change of Certified Adviser to Redeye

Bifogade filer

Nyheter om Magle Chemoswed

Läses av andra just nu

Om aktien Magle Chemoswed

Senaste nytt